Ace the CRNI Challenge 2025 – Infuse Your Career with Success!

The antineoplastic agent with a lifetime cumulative dose limit of 550 mg/m² is Daunorubicin HCI. This drug belongs to the class of anthracyclines, which are known for their effectiveness in treating various cancers, particularly hematological malignancies. However, one of the significant concerns with Daunorubicin is its potential to cause cumulative cardiotoxicity, particularly dose-dependent cardiomyopathy. To mitigate this risk, a lifetime cumulative dose limit has been established.

In contrast, other options such as Bleomycin, Cyclophosphamide, and Etoposide have different considerations for cumulative dosing or side effects, but they do not share the specific lifetime cumulative dose limit as Daunorubicin does. For instance, Bleomycin is known for pulmonary toxicity, and while there is a maximum cumulative dose suggested, it is not the same as the stringent 550 mg/m² limit associated with Daunorubicin. Understanding the specific dose limits associated with different antineoplastic agents is crucial for ensuring patient safety and optimizing cancer treatment strategies.